LIOTHYRONINE MARKET ANALYSIS

Regional Analysis

Global Liothyronine Market Regional Analysis

On the basis of region, global liothyronine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, hypothyroidism is having high prevalence in the U.S. because of decreased thyroid hormone production in individuals, owing to changes in lifestyle and unhealthy diet. For instance, according to the American Thyroid Association report 2019, 12% of the U.S. population suffered from thyroid and 60% of the population were unaware of thyroid related conditions. Therefore, pharmaceutical companies are focusing on product approvals for treatment of hypothyroidism to strengthen their market share. For instance, in 2017, ITL Pharma, Inc. (ITL), a pharmaceutical research company, received approval for its Trithyroid (liothyronine, T3), as a sustain drug release under the category of patent protection by the U.S. Food Drug and Administration.

In Europe, according to the National Institute of Health 2019 report, prevalence of hypothyroidism was 4.49% in the region. Therefore, pharmaceutical companies are focusing on product launches for treatment of hypothyroidism to strengthen their market share. For instance, in 2019, Bioiberica S.A.U, a manufacturer of natural active pharmaceutical ingredients, launched thyroxime and liothyronine from human thyroid glands indicated for the treatment of hypothyroidism.